2026-10-25
Innovex International, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 26,990 +1.35%
S&P 7,377 +0.31%
GOLD $4,080 −0.83%
BTC $75,957 +0.02%
VIX 25.64 −9.01%
latest tape · as of 02:02 UTC
The Screen · Energy · Oil & Gas Equipment & Services
Innovex International, Inc.
INVX · the NYSE · USD · Market cap $1.8B · 2,160 employees
Innovex International, Inc.
Not yet scored24.43 USD
Price as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 02:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price24.43 USD at the 5 Nov 2026 close
- Our value readFair vs our fair value, as of 5 Nov 2026
- Our regime readDistribution, as of 7 Nov 2026
- Ethical screenNot yet scored
- Last reviewed5 Nov 2026 (2 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: $24.30 to $29.14, base estimate $25.34 (screen dated 2026-11-05).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical screen not yet scored
Price24.43 USD
Fair value25.34
Ethical score70.0/100
Value readFairas of 5 Nov 2026
Our investment reviews on this name
2026-11-05Read Distribution25.59-4.5% to today ✓Markdown gives way to Distribution after a 13% slide in 12 days
2026-10-24Read Markdown29.45-17.0% to today ✓Accumulation gives way to Markdown after an 8% rise in 3 days
2026-10-21Read Accumulation27.39-10.8% to today Markdown gives way to Accumulation with results news in the headlines
2026-10-02Read Markdown27.33-10.6% to today ✓Markup gives way to Markdown after an 8% slide in 4 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its distribution label.
Innovex International, Inc. holds its Distribution at $24.43. The statistical read favours the sellers, held for 42 days.
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the sellers, held for 42 days |
| Price at the screen | $24.43 |
| Valuation | 37.09 trailing · 13.37 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 1.12 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 6.25% | Below 33% | Interest-bearing debt is just 6.3% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 34.15% | Below 49% | Money owed to the company is 34.1% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Innovex International, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Innovex International, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 6%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads Fair vs our fair value, as of 5 Nov 2026: it trades at roughly a 4% discount to our $25.34 fair value, 10.40% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 3.6% discount to the base estimate.
Third-party analyst targets: 6 covering, consensus Buy. The average target sits +41% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $25.34, with a range of $24.30 to $29.14, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsOil tools maker stuck in a flat cycle
Picture an oilfield supplier whose kit only earns when drillers are flush. Innovex sits right there, with revenue already slipping one percent and margins stuck at five percent. The forward multiple of 13 times looks modest until you remember this is a cyclical business where peak earnings often arrive just before the next downturn. Fair value sits level with the current price, leaving no margin of safety and no reason to step in.
The low return on equity of five percent tells the same story. Capital is not compounding, the moat is unclear, and growth has turned negative. In equipment and services tied to rig counts, a cheap multiple is usually a warning rather than a bargain, especially when the next oil-price swing can wipe out several years of thin profits.
Ethics clear the screen, yet the numbers still fail on every other test. Five analysts see upside to thirty-five dollars, but that target rests on assumptions that rarely hold through a full cycle. We pass. Analysis, not advice.
| Forward P/E | 13.4xpriced for continued growth |
| Trailing P/E | 37.1xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 0.69 |
| EPS, forward | 1.91 |
| Revenue growth | +10.4%steady growth |
| Profit margin | 4.8%barely profitable |
| Return on equity | 4.5%a modest return on shareholder capital |
| FCF yield | 4.89% |
| Debt to equity | 0.07minimal debt: a conservative balance sheet |
| Current ratio | 4.43comfortably covers its short-term bills |
| Beta | 1.12moves a little more than the market |
| Short interest, float | 0.08% |
| 52-week range | 19.07 - 33.71 |
| Market cap | $1.8B |
| Employees | 2,160 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeINVX trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-05
Distribution · changed $25.59
-14.4% Entry 17
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 14.4% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 11% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (4 analysts) rates it buy, with a mean price target of $32.
2026-10-29
Markdown $29.91
+1.6% Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.6% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 11% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (4 analysts) rates it buy, with a mean price target of $32. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28
Markdown $29.45
+0.0% Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 11% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (4 analysts) rates it buy, with a mean price target of $32. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27
Markdown $29.45
+0.0% Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 11% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (4 analysts) rates it buy, with a mean price target of $32. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26
Markdown $29.45
+0.0% Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 11% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (4 analysts) rates it buy, with a mean price target of $32. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25
Markdown $29.45
+0.0% Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (4 analysts) rates it buy, with a mean price target of $32. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24
Markdown · changed $29.45
+0.0% Entry 11
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (4 analysts) rates it buy, with a mean price target of $32. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23
Accumulation $29.45
+0.0% Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (4 analysts) rates it buy, with a mean price target of $32. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22
Accumulation $29.45
+7.5% Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (4 analysts) rates it buy, with a mean price target of $32. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21
Accumulation · changed $27.39
-2.4% Entry 8
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (4 analysts) rates it buy, with a mean price target of $32.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Is Innovex International (INVX) Undervalued After Q3 Earnings And New Revenue Guidance? Yahoo Finance · 6d ago
- Innovex International (INVX) Secures More Than $30 Million Indonesia Subsea Contract Yahoo Finance · 6d ago
- Innovex (INVX) Q3 2026 Earnings Call Transcript Yahoo Finance · 7d ago
- Innovex International, Inc. Q3 2026 Earnings Call Summary Yahoo Finance · 8d ago
- Innovex International (INVX) Q3 Earnings Miss Estimates Yahoo Finance · 8d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
FLOCFlowco Holdings Inc.
NESRNational Energy Services Reunited Corp.
XPROExpro Group Holdings N.V.
EROKEagleRock Land, LLC
LBRTLiberty Energy Inc.
NEXTNextDecade Corporation
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $27.06 | +6.7% | · | $1,067 | +6.7% |
| 2 months | $26.51 | +8.9% | · | $1,089 | +8.9% |
| 3 months | $24.13 | +19.7% | · | $1,197 | +19.7% |
| 6 months | $23.04 | +25.4% | · | $1,254 | +25.4% |
| 1 year | $16.17 | +78.6% | · | $1,786 | +78.6% |
| 2 years | $18.07 | +59.8% | · | $1,598 | +59.8% |
| 3 years | $25.30 | +14.2% | · | $1,142 | +14.2% |
| 5 years | $37.75 | -23.5% | · | $765 | -23.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever INVX does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.